Active Ras oncogene is expressed in f30% of human cancers.
Introduction
The c-Jun NH 2 -terminal kinase (JNK) belongs to a family of mitogen-activated protein kinases (MAPK), together with the p38 and extracellular regulated kinases (ERK). The JNK subfamily consists of three isoforms: JNK1, JNK2, and JNK3, which can altogether give rise to 10 splice variants. The splice variants differ in their ability to bind substrates like c-Jun (1) and ATF-2, and in the length of their COOH terminus (2, 3) . JNK has been shown to be involved in various very different cellular processes. The data on the functional differences of the specific JNK isoforms or splice variants is just beginning to emerge. Further complexity to JNK signaling is provided by a plethora of JNK upstream kinases and scaffold proteins (4, 5) .
Ras is a small membrane-bound monomeric G protein that transmits and links membrane receptor-mediated extracellular signals to the intracellular signaling network. The Ras family consists of three members: H-Ras, K-Ras, and N-Ras. Mutations resulting in the constitutive activation of all three Ras family members have been detected. Constitutively active mutated Ras oncogenes can be found in 30% of malignant human tumors, which makes it the most common oncogene involved in human cancer (6, 7) . Ras can activate various cellular signaling pathways that promote cell survival and proliferation including Raf, ERK, phosphoinositide-3-kinase (PI3K)-protein kinase B, JNK, and nuclear factor nB pathways. Abrogation of Ras activity by dominant negative effector molecules or Ras pathway inhibitors results in decreased cell survival and proliferation capacity, showing that these cancer-promoting effects of Ras could be reversed (8) (9) (10) (11) . Thus, various strategies to inactivate Ras are currently under investigation for their effectiveness in anticancer therapy.
Very little is known of the actual molecular mechanisms by which Ras transforms cells and what the central mediators for this process are. It has been suggested that the growth-stimulating and -transforming effect of Ras could be largely mediated via c-Jun/ activator protein-1 (AP-1), which is also a central target of JNK signaling (12) . c-Jun is one of the components of the transcription factor AP-1. Supportively, active oncogenic Ras can promote c-Jun phosphorylation and AP-1 activation, whereas c-Jun knockout murine embryonic fibroblasts (MEFs) are completely deficient in Ras transformation (13) (14) (15) . Interestingly, MEFs carrying c-Jun alleles with major JNK phosphorylation sites (serines 63 and 73) mutated to alanines (JunAA) exhibit only f50% reduction in Rasinduced tumorigenesis in vivo as compared with the corresponding wild-type MEFs (16) , suggesting that the c-Jun phosphorylation by JNK is not a requirement for Ras transformation. Another recent study has shown that Jnk-null MEFs exhibit f50% reduction in Ras-mediated transformation in vitro as compared with wild-type MEFs, but are surprisingly clearly more tumorigenic than wild-type cells in vivo (17) . These data point to a rather complicated role for the JNK signaling in Ras transformation.
In order to thoroughly explore the role of JNK and its isoforms in Ras-mediated transformation and tumorigenesis, we used genetic inactivation and RNA interference technology (RNAi). Interestingly, we observed that the Jnk2À/À MEFs were markedly impaired in their ability to be transformed by H-Ras as compared with the corresponding wild-type and Jnk1À/À cells both in vitro and in vivo. Surprisingly, the activation of the transcription factor AP-1, which is the most conventional Ras and JNK signaling target, was not impaired in Jnk2À/À MEFs, revealing the existence of a transformation supporting JNK2 downstream signaling component divergent from AP-1. The H-Ras-expressing Jnk2À/À MEFs could only be transformed by coexpression of either SV40 large T antigen (SV40-LT) or c-Myc, the combination of which is known to be needed for the transformation of primary MEFs, suggesting that the immortalized MEFs lacking JNK2 have gained an extra barrier to protect them from Ras-induced tumorigenicity.
Materials and Methods
Cell culture and retroviral gene transfer. C57BL/6 mice heterozygous for Jnk1 and Jnk2 and their corresponding mutated alleles were crossed (18, 19) . Embryos were harvested at E12 or E14, fibrous tissues were collected, trypsinized, and cultured in DMEM as described previously (20) . Wild-type, Jnk1À/À, and Jnk2À/À fibroblasts were further passaged and allowed to immortalize spontaneously according to the NIH3T3 protocol. The PhoenixEco packaging cells were cultured in DMEM supplemented with 10% FCS, 100 Ag/mL of streptomycin, and 100 units/mL of penicillin. The retroviral gene transfer was done as described previously (20) . Plasmid construction. The viral H-Ras was cloned into retroviral pBabe (pB)-Puro or pB-Hygro expression vectors at the BamHI site. The JNK2 short hairpin RNA constructs, J2sh-1 (GATCCCCGTGAACTCGTCCTCT-TAAATTC AAGAGATTTAAGAGGACGAGTTC ACTTTTTGGAAA/ AGCTTTTCCAAAAAGTGAACTCGTCCTCTTAAATCTCTTGAATTTAAGAG-GACGAGTTCACGGG), J2sh-2 (GATCCCCGTACCCTGGAATCAAGTTTTT-CAAGAGAAAACTTGATTCCAGGGTACTTTTTGGAAA/AGCTTTTCCA-AAAAGTACCCTGGAATCAAGTTTTCTCTTGAA AAACTTGATTCCAGGG-TACGGG), and J2sh-3 (GATCCCCGTGATGGACTGGGAAGAAATTCAAG-AGATTTCTTCCCAGTCCATCACTTTTTGGAAA/AGCTTTTCCAAAAAGT-GATGGACTGGGAAGAAATCTCTTGAATTTCTTCCCAGTCCATCACGGG) were annealed and ligated to the HindIII-BglII linearized pRetro-puro vector using the Rapid ligation kit (Roche, Basel, Switzerland). Four mouse JNK2 splice variants J2a1, J2a2, J2h1, and J2h2 in puromycin-resistant pB vectors (20) were mutated in positions 2, 8, 14, and 17 according to the binding site for J2sh-1. Mutations were introduced two at a time using the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA).
In vitro tumorigenicity assays. For focus formation assays, 200 or 500 cells of the retrovirally transduced MEFs were plated with 8.3 Â 10 5 NIH3T3 as feeder cells per well in a six-well plate. The cells were grown for 1 to 2 weeks and the medium was changed every 3 to 4 days. The plates were washed with PBS and fixed in methanol for 10 min. The fixed cells were then stained with prefiltered 10% Giemsa for 15 min. Ras-transduced wildtype and Jnk1À/À cells were stained after 7 to 10 days and Jnk2À/À and mock controls were stained after a minimum of 14 days. Foci numbers were calculated per 200 infected cells.
For soft agar assay 1.5 mL of 0.5% agar (electrograde ultra pure; Invitrogen, Carlsbad, CA) supplemented with DMEM were plated in six-well plates. Fifteen thousand cells were mixed with 1.5 mL of 0.35% agar supplemented with DMEM and plated on the solidified bottom agar. Media was added on top of the agar layers and the colonies were allowed to grow for 2 to 3 weeks. The colonies were quantified using a light microscope at 10Â magnification.
In vivo tumorigenicity assay. Five million H-Ras-transduced MEFs (in 100 AL of PBS) were s.c. inoculated into the right flank of female BALB/c nude mice. The tumor size was measured each 3rd day in the beginning, and later when the tumors started to grow, more frequently. The mice were sacrificed when the tumor size reached the maximum tolerated size with a diameter of 12 mm, or alternatively, after 3 months if no tumors had developed. The tumor diameter was measured using a caliper.
Western blot analysis. The cell lysates and Western blots were prepared as described before (20) except for the c-Jun, Fra-1, and phospho-c-Jun blot, for which the cells were harvested in 2Â Laemmli sample buffer and sonicated for 10 s in ice prior to SDS-PAGE separation.
Mouse monoclonal antibody Jnk (666) was purchased from PharMingen (San Diego, CA) and anti a-tubulin was from Sigma (St. Louis, MO). p53 antibody was purchased from Oncogene (Cambridge, MA) and p19 Cell growth assay. Cell density was evaluated with the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide reduction assay. The cells were plated at a density of 1,000 cells/well in a 96-well plate 24 h prior to the first time point. Cells were analyzed at the indicated time points. The assay was done as described previously (21), and all time points were assayed as triplicates.
Transient transfection and reporter assays. MEFs were cotransfected with pRL-null renilla luciferase (Promega, Madison, WI) and 4xAP-1 firefly luciferase plasmid using the FuGeneHD transfection reagent (Roche). Cells were lysed 48 h after transfection and the luciferase activity was measured according to the manufacturer's protocol (Dual-Luciferase Assay System; Promega).
Results
Oncogenic Ras signaling requires the JNK2 isoform of JNK.
To investigate the role of the JNK isoforms in Ras transformation, MEFs were isolated from several individual wild-type, Jnk1À/À, and Jnk2À/À embryos and immortalized with the NIH3T3 protocol. Immortalized cells were subsequently subjected to an additional 30 passages and transduced with retroviral pB-H-Ras expression construct. Because JNK3 expression was undetectable in MEFs (22) (Fig. 1B) . Interestingly, it was previously reported that the Jnk2À/À primary MEFs grow faster than the corresponding wild-type and Jnk1À/À MEFs (24) . This is exactly what we have also observed with the primary Jnk2À/À MEFs.
2 Ras-transduced Jnk2À/À MEFs were also deficient in their ability to grow both anchorage-independently in soft agar and anchorage-dependently in culture dishes ( Fig. 1C and D) . Whereas the H-Ras-transduced Jnk1À/À MEFs exhibited thin, elongated, and spindle-like morphology and loss of contact inhibition characteristic of transformed fibroblasts, the H-Rastransduced Jnk2À/À MEFs retained the nontransformed morphology comparable to that of the vector-transduced control cells and were not capable of multilayer growth when seeded at a higher density (Fig. 1D) . Accordingly, Jnk2À/À MEFs exhibited severely reduced tumorigenic potential when injected s.c. into BALB/c nude mice. Although the wild-type and the Jnk1À/À MEFs produced tumors with a 12 mm diameter at an average of 13.1 and 10.9 days, respectively, one of the H-Ras-transduced Jnk2À/À MEF lines (J2-2, n = 4) did not form any measurable tumors during the 3-month observation period, and the other Jnk2À/À MEF line (J2-1, n = 4) took 26.3 days to form 12 mm tumors (Table 1) . Taken together, these data show that H-Ras failed to transform the Jnk2À/À MEFs.
Down-regulation of JNK2 by RNAi in wild-type MEFs impairs the capability of Ras to transform them. In order to study if the down-regulation of JNK2 in the wild-type MEFs would have similar effects to the H-Ras-induced transformation as the genetic inactivation, we prepared three retroviral short hairpin constructs against JNK2 (J2-sh1, J2-sh2, and J2-sh3) and tested their ability to down-regulate JNK2 protein levels. Both J2-sh1 and J2-sh3 clearly down-regulated the 55 kDa form of JNK in the wild-type cells ( Fig. 2A, left blot) , which is the major JNK2 form in the MEFs (see Fig. 1A , middle). The expression of these constructs in Jnk1À/À cells further showed that they were very efficient in down-regulating JNK2 ( Fig. 2A, middle blot) . Furthermore, the two most efficient hairpins (J2-sh1 and J2-sh3) had no detectable effect on the expression of the JNK1, as shown in the Jnk2À/À cells ( Fig. 2A, right blot) . To test the ability of these hairpins to reduce the tumorigenicity of the wild-type MEFs, they were first used to down-regulate JNK2 in the wild-type cells, after which the cells were transduced with H-Ras. Down-regulation of JNK2 prior to H-Ras transduction clearly reduced the tumorigenicity of wild-type cells (Fig. 2B) . The ability of the JNK2 down-regulation to affect focus formation of the H-Ras-transformed wild-type cells was also tested. Down-regulation of JNK2 after Ras transformation did not have any measurable effects on the tumorigenicity of the wildtype MEFs (Fig. 2C) . Coexpression of all four J2-sh1 recognition site-mutated JNK2 splicing variants in the J2-sh1 and H-Rastransduced wild-type cells rescued the transformation-deficient phenotype (Fig. 2D) . The expression levels of the mutated JNK2 splicing variants vary somewhat, probably due to the fact that ectopic Ras could up-regulate the expression of the retroviral LTR promoter. The ectopic expression of the four JNK2 splicing variants in Jnk2À/À MEFs failed, however, to augment the H-Ras-mediated transformation (data not shown). Overall, we can conclude from the RNAi data that the inactivation of the JNK2 has an effect on the tumorigenicity when it occurs prior to Ras transformation, further supporting the role of JNK2 in the early phase of Ras transformation.
Deficiency for Ras transformation in Jnk2À/À MEFs is not due to the lack of Ras-responsive c-Jun phosphorylation or AP-1 activation. Because c-JunÀ/À MEFs cannot form multilayer foci upon expression of oncogenic Ras (14), we next tested if the deficient Ras transformation of the Jnk2À/À MEFs would be due to the inability of these cells to activate c-Jun and AP-1. We tested their ability to accumulate AP-1 components, c-Jun and Fra-1, a typical feature for Ras-transformed fibroblasts due to the fact that Ras can induce AP-1 activation, and both c-Jun and Fra-1 genes are regulated by AP-1 (25) . H-Ras-transduced Jnk2À/À MEFs were just as capable of accumulating both c-Jun and Fra-1 as the (Fig. 3A) . Furthermore, phosphorylation of c-Jun was just as efficient in Rastransduced Jnk2À/À as it was in corresponding wild-type and Jnk1À/À MEFs (Fig. 3A) . We also tested the AP-1 reporter activity in these cell lines and found that the Jnk2À/À MEFs were slightly more efficient in activating AP-1 than the wild-type and Jnk1À/À MEFs both in response to H-Ras and MAPK kinase kinase (MEKK1), an efficient JNK and AP-1 activator (Fig. 3B) . We conclude from these data that the Jnk2À/À MEFs are capable of activating c-Jun and AP-1, and that the deficiency of Ras transformation in the Jnk2À/À MEFs is not due to defective activation of c-Jun/AP-1.
The deficient Ras transformation of the Jnk2À/À cells does not involve p53 activity or incomplete immortalization. The spontaneous immortalization (NIH3T3 method) of mouse fibroblasts involves inactivation of the p53 tumor suppressor pathway. Thus, the introduction of a single transforming oncogene, like Ras, is sufficient to transform them (26) . Because the immortalized Jnk2À/À MEFs cannot be transformed with H-Ras alone, we studied if these cells had failed to immortalize and still had active p53 pathways. For this purpose, we tested the expression of p53 and p19
Arf in these cells. One of the tested wild-type (wt-1) and two Jnk1À/À (J1-1 and J1-2) MEF lines had clearly accumulated p53 expression indicative of an inactivating mutation in p53 (Fig. 4A, top) . Because none of the Jnk2À/À MEFs exhibited strong p53 accumulation, we also evaluated the expression of the p19 Arf by Western blotting. We found out that all the Jnk2À/À MEFs had lost the expression of p19 Arf , and could therefore be classified as ''immortal'' according to these criteria (Fig. 4A, middle) . Furthermore, we also ''forced'' the p53 pathway inactivation in Jnk2À/À and wild-type MEFs by overexpression of the E6 protein of the human papillomavirus E16, which is known to efficiently inactivate Figure 2 . Down-regulation of JNK2 by RNAi prior to H-Ras transformation reduces the tumorigenicity of the wild-type MEFs. A, the specificity of three prepared short hairpin RNAs against JNK2 (J2sh-1, J2sh-2, and J2sh-3) was evaluated by Western blotting. JNK expression was investigated in wild-type, Jnk1À/À, and Jnk2À/À MEFs stably expressing J2sh-1, J2sh-2, and J2sh-3. a-Tubulin was used as a loading control. B, focus formation assay of wild-type MEFs from JNK2 down-regulated by J2sh-1 and J2sh-3 and subsequently transformed with H-Ras (left ). Columns, means from one experiment done in triplicate; bars, SD (***, P < 0.001). The experiment was repeated twice with similar results. Western blot analysis was used to evaluate the expression of JNK and H-Ras in wild-type MEFs infected with J2sh-1 and J2sh-3 and with H-Ras. a-Tubulin was used as a loading control. C, focus formation assay of wild-type MEFs infected with H-Ras and subsequently with J2sh-1 or J2sh-3. Columns, means from one experiment done in triplicate; bars, SD. The experiment was repeated twice with similar results. Expression of JNK and Ras in H-Ras-transformed wild-type MEFs infected with J2sh-1 and J2sh-3 was evaluated by Western blot analysis. a-Tubulin was used as a loading control. D, focus formation assay of wild-type MEFs infected with a pool of all four mutated Jnk2 splice variants (mut-Jnk2) or vector control before infection with J2sh-1 and subsequently transformed with H-Ras (left ). Columns, means from one experiment done in triplicate; bars, SD. The experiment was repeated twice with similar results. The JNK and H-Ras expression was evaluated by Western blot. a-Tubulin was used as a loading control (right ). the p53 pathway (27) . Coexpression of the E6 protein together with Ras was still not sufficient for transforming Jnk2À/À MEFs (Fig. 4B) , further suggesting that the defect in Ras transformation in the Jnk2À/À MEFs is not due to the defective inactivation of the p53 pathway. Because all of the above described experiments were done at passages 30 to 35, we passaged the cells 30 more times to ensure that they were immortal, and tested their capability for transformation by H-Ras to find out if it would improve on passage number, time, and handling. At passage 65, Jnk2À/À MEFs grew slightly faster than on passages 30 to 35 (data not shown), but were still deficient in Ras transformation (Fig. 4C) . Thus, we conclude that the deficiency in Ras transformation in Jnk2À/À MEFs was not due to incomplete immortalization.
Jnk2À/À MEFs can be transformed by Ras when cotransduced with a Ras-cooperating oncogene. Because immortalized Jnk2À/À MEFs could not be transformed with Ras, which is a strongly transforming oncogene and is normally sufficient by itself to transform immortalized murine fibroblasts, we tested if the coexpression of a Ras-cooperating oncogene would be able to transform them similar to primary fibroblasts (28, 29) . Indeed, coexpression of SV40-LT and H-Ras in Jnk2À/À MEFs efficiently transformed these cells as analyzed by the focus formation assay (Fig. 5A, left and B) . Similarly, another Ras-cooperating oncogene, c-Myc, assisted H-Ras-expressing Jnk2À/À MEFs to form foci (Fig. 5A, right and B) . In addition to the ability to form foci, coexpression of SV40-LT or c-Myc together with H-Ras in Jnk2À/À MEFs resulted in clearly transformed cellular morphologies similar to that of the corresponding wild-type cells (Fig. 5C) . The phospho-c-Jun Western blot analysis also failed to show any clear correlation between the transformation capability and c-Jun phosphorylation in these cells (Fig. 5D ). This data strongly suggests that the lack of JNK2 created an extra protective barrier in these cells against Ras transformation that could be overcome by coexpression of cooperating oncogenes and was not dependent on c-Jun phosphorylation.
Discussion
The data presented above clearly shows that the JNK2 isoform of JNK is indispensable for the Ras transformation process in MEFs. The fact that the Ras-transduced Jnk1À/À MEFs expresses similar amounts of JNK compared with the corresponding Jnk2À/À MEFs (Fig. 1A, middle) , and the fact that they do not have any defect in Ras transformation, indicates that the JNK2 isoform of JNK is specifically supporting Ras transformation and that the results reported above are not just due to a possible overall lower level of JNK expression in Jnk2À/À MEFs. Furthermore, because retrovirally transduced H-Ras was expressed in the Jnk2À/À cells as efficiently as in the corresponding wild-type and Jnk1À/À cells, the defect in Ras transformation in Jnk2À/À MEFs was not due to lower Ras levels either, which have previously been shown to influence Ras transformation efficiency (23) . Thus, our data clearly points out that selective inactivation of the JNK signaling pathway by preventing the expression of the JNK2 isoform of JNK impairs Ras transformation.
It is very surprising that inactivation of only one isoform of JNK can have so drastic an effect in the Ras transformation process. In order to rule out the possibility that the MEFs used in this study might have abnormal Ras signaling, we transduced them with the dominantly active Ras effector loop mutants; 12V35S, 12V37G, and 12V40C. These mutants have different preferences in the activation of Ras downstream signaling pathways in NIH3T3 murine fibroblasts, 12V35S being the most prominent in activating the Raf-MEK pathway, 12V37G the Ral-JNK, and 12V40C the PI3K-protein kinase B pathways (30) . Ras signaling in MEFs did not exhibit differences in the pattern of activation of these three effector pathways in comparison with NIH3T3 fibroblasts, but instead were activated in an identical manner, 3 showing that the MEFs used in this study exhibit normal Ras signaling. Supporting our data, earlier in vivo studies on murine 7,12-dimethylbenz(a) anthracene (DMBA)/12-O-tetradecanoylphorbol-13-acetate (TPA) induced skin tumorigenesis showed that the Jnk2À/À mice were resistant to tumor formation, whereas Jnk1À/À mice were not (31, 32) . Because DMBA/TPA treatment could induce H-Rasactivating mutations in mouse skin (33) , these findings and the data presented in this article provide strong evidence for the active role of the JNK2 isoform of JNK, and that it is one of the key players in the Ras transformation process in the mouse.
A previous partially contradictory study involving the ectopic expression of oncogenic H-Ras in a Jnk-null MEF line showed only f50% reduction in the transformation efficiency in vitro. Furthermore, ''s.c. tumors were detected in all mice injected with H-Ras-transformed wild-type or Jnk-null cells'' but strikingly, the tail vein injections of the H-Ras-expressing Jnk-null cells resulted in ''lung tumor nodules with substantially greater tumor mass'' than the wild-type cells. Interestingly, in that study, expression of JNK1 or JNK2 in the Jnk-null cells resulted in decreased tumor mass, complementing the effect of JNK deficiency and leading to the conclusion that JNK could act as a tumor suppressor in vivo (17) . It is notable that we have not observed decreased tumorigenicity in our Jnk1À/À MEFs in vitro or in vivo even though we also use an immunodeficient mouse xenograft model. Furthermore, the DMBA/TPA treatment of Jnk1À/À mice led to increased rather than decreased tumorigenicity in vivo (32) . The actual Arf expression in wild-type, Jnk1À/À, and Jnk2À/À MEFs. a-Tubulin was used as a loading control. B, focus formation assay with wild-type and Jnk2À/À MEFs infected with E16E6 alone or in combination with H-Ras. Columns, means from one experiment done in triplicate; bars, SD. The experiment was repeated thrice with similar results. C, focus formation of the wild-type, Jnk1À/À, and Jnk2À/À MEFs that were passaged for an additional 65 times, and subsequently transduced with H-Ras. Columns, means from one experiment done in triplicate; bars, SD.
reason for this clear difference may be very difficult to pinpoint, but some of it could be due to differences in the knockout mouse backgrounds. It could also be influenced by the fact that the Jnk-null MEFs are extremely difficult to establish because JNK is important for cellular survival, and the Jnk-null mice die at embryonic days 10 to 11 (34, 35) , suggesting that the Jnk-null MEFs may have undergone major changes in order to survive, which might also affect their Ras-inducible tumorigenicity.
Several studies suggest an active role for JNK signaling in human cancer. For example, down-regulation of JNK2 with antisense oligos has been shown to cause growth inhibition in human T98G glioblastoma and prostate carcinoma cells (36, 37) , as well as inhibition of epidermal growth factor-induced proliferation of human A549 lung carcinoma cells (38) . Thus far, however, constituent JNK activation in cancer cells has only been found in human glioblastomas (39, 40) . Additionally, contrary to the above findings, an upstream kinase of JNK, MAPK kinase 4 (MKK4), has been suggested to be a metastasis suppressor because some human breast, pancreatic, biliary, ovarian, and prostate carcinomas have been found to exhibit no or reduced expression levels of MKK4 compared with corresponding nonmalignant tissue (41) (42) (43) . These data, altogether, point towards a rather complicated role for the JNK signaling pathway in cancer.
Utilization of the Ras effector loop mutants that can preferentially activate the Raf-MEK-ERK, Ral-JNK, or PI3K pathways has shown that in human cells, the activation of the Ral-JNK pathway was the most transforming and the Raf-MEK-ERK the second most transforming, suggesting that the Ras transformation process may differ between human and mouse cells (44) . However, one should notice that these mutants function preferentially, but not exclusively, on the designated effector pathways, and furthermore, that they do not cover all signaling pathways downstream of Ras, such as, for example, the Rac-PAK pathway whose activation leads to JNK activation in Ras-transformed Rat-1 cells (45) . Interestingly, our data showing that JNK2 has a crucial role in Ras transformation of MEFs, together with the previous study (44) , supports the existence of a transformation model in which the importance of the JNK pathway could be more universal between human and mouse in Ras-induced tumorigenesis than previously suggested.
Very little data exists on how Ras actually transforms cells. MEFs immortalized by the NIH3T3 method have been widely used to study the Ras transformation processes because ectopic expression of active oncogenic Ras alone is capable of transforming these cells (26) . Because c-JunÀ/À MEFs are fully resistant to Ras transformation, and because activation of the transcription factor AP-1 and consequent accumulation of the AP-1 components, c-Jun and Fra-1, could be detected in Ras-transformed wild-type but not in corresponding c-JunÀ/À MEFs, it has been suggested that the c-Jun/AP-1 activation is one of the key events leading to transcriptional changes required for the Ras transformation process (14, 25) . However, an AP-1 target gene, whose protein product would be indispensable for Ras transformation, is yet to be identified. One of the suggested candidates has been cyclin D1 because transcription from the cyclin D1 promoter could be regulated by AP-1 (46) . However, cyclin D1À/À MEFs are not impaired in Ras transformation (47) . Moreover, by showing that the Jnk2À/À MEFs are not deficient in Ras-induced c-Jun phosphorylation or AP-1 activation, our data challenges the role of JNK in the phosphorylation of c-Jun as well as the central role of AP-1 in the Ras transformation process. Thus, as such, it also supports the recent in vivo study showing that JunAA MEFs are only partially resistant to Ras-induced tumor formations (16) . Furthermore, our data clearly points out that JNK2 substrates other than c-Jun or any other AP-1 components are crucial for regulating Ras transformation.
Ras-transduced Jnk2À/À MEFs show several phenotypes that are typical for nontransformed primary embryonic fibroblasts: Ras-transduced Jnk2À/À MEFs are contact-inhibited, they have a growth disadvantage, and they enter an initial crisis upon Ras transduction which they overcome in 2 to 3 weeks (data not shown). In addition, they exhibit impaired migration (data not shown), multilayer formation, anchorage-independent growth, and tumor formation in mice. Compiling all of these phenotypes suggests that JNK2 has a very central role in the regulation of Ras transformation. Furthermore, akin to primary MEFs, Jnk2À/À MEFs can be fully transformed by coexpression of H-Ras with SV40-LT or c-Myc. A similar phenotype was observed with the CDK4À/À MEFs, which could not be transformed with Ras, suggesting that a critical threshold for CDK4 activity was required for oncogenic cell cycling (48) . However, Ras expression in CDK4À/À MEFs rendered them into a state resembling premature senescence (48), which does not seem to be the case in Jnk2À/À MEFs. It remains to be seen if JNK2 can control the activities of CDK or whether the mechanism involving JNK2 in Ras transformation is something very different.
The data obtained in this study gives novel important information on the Ras transformation process. It clearly points out that the JNK signaling pathway, and especially the JNK2 isoform of JNK, can mediate the transforming signal of Ras and is required for the development of Ras-induced tumorigenicity. Furthermore, our data shows that Ras transformation of the immortalized fibroblasts which carry genetically inactivated JNK2 requires the coexpression of a cooperating oncogene, showing that the JNK2 inactivation in these cells created an extra protective barrier against Ras transformation. Importantly, our data also strongly suggests that the activation of a JNK2 target other than c-Jun is crucial for the Ras transformation process.
